false
0001708599
0001708599
2024-02-01
2024-02-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): February 1, 2024
AgeX
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
1-38519 |
|
82-1436829 |
| (State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
1101
Marina Village Parkway
Suite
201
Alameda,
California 94501
(Address
of principal executive offices)
(510)
671-8370
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of exchange on which registered |
| Common
Stock, par value $0.0001 per share |
|
AGE |
|
NYSE
American |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☒ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On
February 1, 2024, AgeX Therapeutics, Inc. (“AgeX”) drew $500,000 of its credit available under the Amended and Restated Secured
Convertible Promissory Note (as amended, the “Secured Note”) with Juvenescence Limited (“Juvenescence”).
The
Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.
The other material terms of the Secured Note are summarized in AgeX’s Quarterly Report on Form 10-Q filed with the U.S. Securities
and Exchange Commission (the “SEC”) on November 14, 2023.
Item
3.02 Unregistered Sales of Equity Securities.
On
February 1, 2024, AgeX issued to JuvVentures (UK) Limited (“JuvVentures”), a wholly owned subsidiary of Juvenescence, 29,388,888
shares of AgeX common stock, par value $0.0001 per share (“Common Stock”), upon the automatic conversion of 211,600 shares
of AgeX Series A Preferred Stock and 20,611,111 shares of Common Stock upon the upon the automatic conversion of 148,400 shares of AgeX
Series B Preferred Stock held by JuvVentures (the “Conversion”). The shares of Common Stock were issued in the Conversion
without registration under the Securities Act of 1933, as amended, in reliance upon an exemption pursuant to Section 3(a)(9) thereof.
Item
5.01 Changes in Control of Registrant.
The
information disclosed in Item 3.02 of this Report is incorporated into this Item by reference. Based on information reported by Juvenescence
in an amendment to its Schedule 13D filed with the SEC on February 5, 2024, as a result of the Conversion, Juvenescence, through
JuvVentures, holds of record 66,447,499 issued and outstanding shares of Common Stock, representing 75.6% of the shares
of Common Stock issued and outstanding as of the close of business on February 1, 2024, without taking into account additional shares
of Common Stock that Juvenescence may acquire through the conversion of certain outstanding indebtedness and the exercise of certain
outstanding Common Stock purchase warrants that Juvenescence holds. Prior to the Conversion, Juvenescence was already deemed to have
beneficially owned the shares of Common Stock issuable in connection with the Conversion, and Juvenescence reported beneficially owning
those shares of Common Stock in its Schedule 13D prior to the Conversion such that the Conversion did not result in a change in
Juvenescence’s beneficial ownership of Common Stock. However, because the number of issued and outstanding shares of Common Stock
held of record by JuvVentures and beneficially owned by Juvenescence following the Conversion exceeds 50% of all issued and outstanding
shares of Common Stock, Juvenescence now has voting power over a majority of the outstanding shares of the Common Stock, and a change
of control of AgeX may be deemed to have occurred as a result of the Conversion.
As
a controlling stockholder holding more than 50% of the outstanding shares of Common Stock through its subsidiary JuvVentures, Juvenescence
has the power to elect all members of AgeX’s board of directors (the “Board of Directors”) and to approve or reject
all matters submitted for stockholder approval by the Board of Directors, by Juvenescence as a stockholder, or by other stockholders,
including, but not limited to: equity compensation plans for employees, officers, and directors; mergers, acquisitions, and consolidations;
sales of AgeX assets; and amendments of AgeX’s certificate of incorporation and bylaws, including all matters that AgeX plans to
submit to AgeX stockholders for approval (the “Stockholder Matters”) at a special meeting of stockholders to be called pursuant
to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) between AgeX, Serina Therapeutics, Inc.,
an Alabama corporation (“Serina”), and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary
of AgeX (“Merger Sub”). Concurrently with the execution of the Merger Agreement, Juvenescence entered into a support agreement
in favor of Serina, providing, among other things, that Juvenescence will vote all of its shares of Common Stock: (i) in favor of adopting
the Merger Agreement and approving the proposed merger of Merger Sub with and into Serina, with Serina surviving as a wholly owned subsidiary
of AgeX (the “Merger”) and the Stockholder Matters, and the other transactions and actions contemplated by the Merger Agreement
(together with the Merger, the “Contemplated Transactions”); (ii) against any proposal made in opposition to, or in competition
with, the Merger Agreement or the merger; and (iii) against any acquisition proposal involving a third party other than Serina. If the
Merger is consummated in accordance with the terms of the Merger Agreement, immediately following the Merger, equity holders of Serina
immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of Common Stock of AgeX,
and equity holders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares
of Common Stock of AgeX, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the
actual closing price of Common Stock being equal to or greater than $12.00 per share (on a post-reverse stock split basis), giving effect
to a proposed reverse stock split and excluding the impact of a proposed warrant dividend. Accordingly, it is expected that the shares
of Common Stock now beneficially owned by Juvenescence would represent substantially less than 50% of the outstanding shares of Common
Stock immediately after the Merger as a result of the issuance of shares of Common Stock to securities holders of Serina pursuant to
the Merger Agreement.
Presently,
one member of the Board of Directors, Gregory H. Bailey, is a director of Juvenescence, while a majority of our directors are “independent”
directors as defined in the NYSE American Company Guide (the “Company Guide”), and the Audit Committee, Compensation Committee,
and the Nominating & Corporate Governance Committee of our Board of Directors are comprised entirely of independent directors. While
Juvenescence controls more than 50% of the outstanding Common Stock, AgeX will qualify as a “controlled company” as defined
by the Company Guide. Being a “controlled company” will allow AgeX to exempt itself from the requirements that a majority
of its directors be “independent” directors as defined in the Company Guide and that the Compensation Committee and the Nominating
& Corporate Governance Committee be comprised entirely of independent directors. The exemption does not apply to the Audit Committee
which must be comprised of independent directors. If AgeX were to take advantage of any or all of these exemptions available to controlled
companies under the Company Guide, it would be required to disclose doing so in its annual meeting proxy statement or in its Annual Report
on Form 10-K.
Item
8.01 Other Events.
In
accordance with Section 9.1(b) of the Merger Agreement, on February 1, 2024, AgeX provided a written notice to Serina that extended by
60 calendar days the date by which the Contemplated Transactions must be consummated before unilateral termination becomes available
to AgeX or Serina (the “End Date”).
The
End Date was extended from February 29, 2024 to April 29, 2024.
Cautionary
Statement Regarding Forward-Looking Statements
Certain
statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements
regarding the repayment date of the Secured Note, AgeX’s plans to submit matters to AgeX stockholders for approval at a special
meeting of stockholders, AgeX’s qualification as a controlled company and related effects, the anticipated completion and effects
of the proposed merger and related timing, pro forma descriptions of the combined company, Serina’s and the combined company’s
planned preclinical and clinical programs, including planned clinical trials, the potential of Serina’s product candidates, the
anticipated cash expected from warrant exercises and the ability for proceeds to fund the operations of the combined company for as long
as anticipated, the expected trading of the combined company’s stock on the NYSE American under the ticker symbol “SER”,
management of the combined company and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts
for the future. All forward-looking statements are based on assumptions or judgments about future events and economic conditions that
may or may not be correct or necessarily take place and that are by their nature subject to significant risks, uncertainties and contingencies.
You are cautioned not to place undue reliance on these forward-looking statements. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. Statements that contain words such as “anticipates,” “believes,”
“plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,”
“should,” “could,” “estimates,” “predicts,” “potential,” “continue,”
“guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor
provisions of the PSLRA.
There
are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included
in this communication. With respect to the merger, these risks and uncertainties include: the possibility that stockholders of AgeX or
Serina may not approve the merger; one or more conditions to consummating the merger may not be satisfied; one or more material agreements
that may be entered into in connection with the merger may be terminated by a party to the agreement; AgeX or the combined company may
be unable to obtain approval to list on the NYSE American the shares of AgeX common stock expected to be issued pursuant to the merger;
and the closing of the merger might be delayed or not occur at all. In addition, the merger could cause AgeX to face additional risks,
including risks associated with conducting and financing Serina’s current or future research and product development programs,
including risks that those research and development programs will not result in the development of products or technologies with the
desired clinical utility, benefits, or market acceptance; risks associated with conducting clinical trials of Serina product candidates
and obtaining Food and Drug Administration or other regulatory approvals to market product candidates, including risks with respect to
the timing of initiation of Serina’s planned clinical trials, the timing of the availability of data or other results from clinical
trials, and the timing of any planned investigational new drug application or new drug application; risks associated with the combined
company’s ability to identify additional products or product candidates with significant commercial potential; risks associated
with AgeX’s, Serina’s or the combined company’s ability to protect its intellectual property position; product liability
risks; the risk that the cash balance of the combined company following the closing of the merger will be lower than expected or reduced;
the risk that the combined company’s anticipated sources and related timing of financing following the closing of the merger will
not provide proceeds necessary to fund the operations of the combined company for as long as anticipated; the risk that the transactions
contemplated by the Side Letter entered into by AgeX, Serina and Juvenescence on August 29, 2023 are not completed in a timely manner
or at all; risks associated with AgeX’s or Serina’s estimates regarding future revenue, expenses, capital requirements, and
need for additional financing following the merger; risks associated with the ability of AgeX and the combined company to remain listed
on the NYSE American; the risk that products may not be successfully commercialized or that the combined company might not otherwise
be able to generate sufficient revenues to operate at a profit; potential adverse changes to business or employee relationships, including
those resulting from the announcement or completion of the merger; the risk that changes in AgeX’s capital structure, management,
business, and governance following the merger could have adverse effects on the market value of its common stock; the ability of AgeX
and Serina to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers; risks
associated with Serina’s or the combined company’s ability to successfully collaborate with Serina’s existing collaborators
or enter into new collaborations, or to fulfill its obligations under any such collaboration agreements; risks associated with the combined
company’s commercialization, marketing and manufacturing capabilities and strategy; the risk that pursuing and completing the merger
and related transactions could distract AgeX and Serina management from their respective ongoing business operations or cause AgeX and
Serina to incur substantial costs; risks associated with competition and developments in the industry in which the combined company will
operate; the impact of world health events, including the COVID-19 pandemic and any related economic downturn; the risk of changes in
governmental regulations or enforcement practices; AgeX’s and Serina’s ability to meet guidance, market expectations, and
internal projections; the impact of AgeX stockholders having their percentage ownership interests in AgeX reduced by the issuance of
AgeX common stock to Serina stockholders in the merger and by the issuance of shares of AgeX common stock upon the exercise of Post-Merger
Warrants by Juvenescence, and other important factors that could cause actual results to differ materially from those projected or expected
by AgeX management or stockholders. The effects of such factors are difficult to predict and may be beyond AgeX’s or Serina’s
control.
New
factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such
factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from
those contained in any forward-looking statements. Additional factors that could cause actual results to differ materially from the results
anticipated in these forward-looking statements are contained in AgeX’s periodic reports filed with the U.S. Securities and Exchange
Commission (“SEC”) under the heading “Risk Factors” and other filings that AgeX may make with the SEC. Forward-looking
statements included in this communication are based on information available to AgeX and Serina as of the date of this communication.
Undue reliance should not be placed on these forward-looking statements that speak only as of the date they are made, and except as required
by law, AgeX and Serina each disclaims any intent or obligation to update these forward-looking statements.
Additional
Information and Where to Find It
In
connection with the proposed business combination transaction between AgeX and Serina, AgeX filed a registration statement on Form S-4/S-1
with the SEC on November 14, 2023, as amended on January 16, 2024 (as amended, the “Form S-4/S-1”). The Form S-4/S-1 contains
a preliminary proxy statement/prospectus of AgeX and a preliminary information statement of Serina (the “Preliminary Proxy Statement/Prospectus/Information
Statement”). The Preliminary Proxy Statement/Prospectus/Information Statement is not final and may be further amended. AGEX URGES
INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT AGEX, SERINA AND THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders will be able to
obtain free copies of the Form S-4 and other documents filed by AgeX with the SEC (when they become available) through the website maintained
by the SEC at www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of the Form S-4 and other documents
filed by AgeX with the SEC by contacting Andrea Park by email at apark@agexinc.com. Investors and stockholders are urged to read the
Form S-4, including the proxy statement / prospectus contained therein, and the other relevant materials when they become available before
making any voting or investment decision with respect to the proposed transaction.
Participants
in the Solicitation
AgeX
and Serina, and each of their respective directors and executive officers and certain of their other members of management and employees,
may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about AgeX’s
directors and executive officers is included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with
the SEC on March 31, 2023, in the proxy statement for AgeX’s 2023 annual meeting of stockholders, filed with the SEC on November
7, 2023, as supplemented by the supplement to the proxy statement for AgeX’s 2023 annual meeting of stockholders, filed with the
SEC on November 14, 2023, and in AgeX’s Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023, filed
with the SEC on November 14, 2023. Additional information regarding these persons and their interests in the transaction are included
in the Preliminary Proxy Statement/Prospectus/Information Statement. These documents can be obtained free of charge from the sources
indicated above.
No
Offer or Solicitation
This
communication relates to a proposed business combination transaction between AgeX and Serina. This communication is for informational
purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any
vote or approval, in any jurisdiction, pursuant to the proposed business combination transaction or otherwise, nor shall there be any
sale, issuance, exchange or transfer of the securities referred to in this communication in any jurisdiction in contravention of applicable
law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
AGEX
THERAPEUTICS, INC. |
| |
|
|
| Date:
February 6, 2024 |
By: |
/s/
Andrea E. Park |
| |
|
Chief
Financial Officer |
v3.24.0.1
Cover
|
Feb. 01, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Feb. 01, 2024
|
| Entity File Number |
1-38519
|
| Entity Registrant Name |
AgeX
Therapeutics, Inc.
|
| Entity Central Index Key |
0001708599
|
| Entity Tax Identification Number |
82-1436829
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
1101
Marina Village Parkway
|
| Entity Address, Address Line Two |
Suite
201
|
| Entity Address, City or Town |
Alameda
|
| Entity Address, State or Province |
CA
|
| Entity Address, Postal Zip Code |
94501
|
| City Area Code |
(510)
|
| Local Phone Number |
671-8370
|
| Written Communications |
true
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
| Trading Symbol |
AGE
|
| Security Exchange Name |
NYSEAMER
|
| Entity Emerging Growth Company |
true
|
| Elected Not To Use the Extended Transition Period |
true
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
AgeX Therapeutics (AMEX:AGE)
過去 株価チャート
から 11 2024 まで 12 2024
AgeX Therapeutics (AMEX:AGE)
過去 株価チャート
から 12 2023 まで 12 2024
